Eupraxia Pharmaceuticals (EPRX) gained retail attention after reporting strong data from its Phase 1b/2a trial for eosinophilic esophagitis. The EP-104GI study showed remission rates of 59% at 12 weeks and up to 76% at 24 weeks. The company noted improved swallowing scores and no serious adverse events. Eupraxia's Diffusphere technology enables precise drug delivery.